

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-25)	IZURALIMAB
PRONUNCIATION	iz" ur a' li mab
THERAPEUTIC CLAIM	Immunomodulator, antineoplastic

## CHEMICAL NAMES

1. Immunoglobulin, anti-(human programmed cell death 1) (human-Mus musculus monoclonal XmAb23104 single-chain variable fragment VL-linker-VH) fusion protein with immunoglobulin G1 (human  $\gamma$ 1-chain C-region C-terminal fragment), (260→234'),(263→237')-bis(disulfide) with immunoglobulin G1-anti-(human inducible costimulator) (human monoclonal XmAb23104  $\gamma$ 1-chain) disulfide with human monoclonal XmAb23104  $\kappa$ -chain
2. Immunoglobulin half-IG G1-kappa/scFv-h-CH2-CH3, anti- [Homo sapiens ICOS (inducible T-cell costimulatory, activation-inducible lymphocyte immunomediatory molecule, AILIM, CD278)] and anti-[Homo sapiens PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody, bispecific; gamma1 heavy chain anti-ICOS (1-454) [VH (Homo sapiens IGHV1-2\*02 (99%) -(IGHD) -IGHJ3\*02 (100%)) CDR-IMGT [8.8.18] (26-33.51-58.97-114) (1-125) -Homo sapiens IGHG1\*03v, G1m3>G1m17, nG1m1 (CH1 N114>D (216) R120>K (222) (126-223), hinge 1-15 (224-238), CH2 E1.4,L1.3>P (241), L1.2>V (242), G1.1>A (243), S29>K (274), Q84.2>E (302) (239-347), CH3 E12 (363), M14 (365), L24>D (375), K26>S (377), N44>D (391), Q97>E (425), N100>D (428), M107>L (435), N114>S (441) (348-452), CHS (453-454)) (126-454)], (228-214')-disulfide with kappa light chain anti-ICOS (1'-214') [V-KAPPA (Homo sapiens IGKV1-12\*01 (96.8%) -IGKJ1\*01 (100%)) CDR-IMGT [6.3.9] (27-32.50-52.89-97) (1'-107') -Homo sapiens IGKC\*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; IG scFv-h-CH2-CH3 single chain, anti-PDCD1 (1''-480'') [scFv-V-kappa-VH anti-PDCD1 (1''-249'')[V-KAPPA (Homo sapiens IGKV3-15\*01 (80.0%) -IGKJ4\*01 (100%)) CDRIMGT [6.3.9] (27-32.50-52.89-97) (1''-107'') -20-mer tetrakis(glycyl-lysyl-prolyl-glycyl-seryl) linker (108''-127'') -VH (Mus musculus IGHV6-6\*02 (87.0%) -(IGHD) -IGHJ1\*03 (86.7%)/Homo sapiens IGHV3-15\*07 (81.8%) -(IGHD) -IGHJ2\*01 (93.3%)) CDR-IMGT [8.10.13] (153-160.178- 187.226-238) (128''-249'')] -Homo sapiens IGHG1\*03 h-CH2- CH3, nG1m1 (250''-480'') [hinge 1-15 C5>S (254) (250-264) - CH2 E1.4,L1.3>P (267), L1.2>V (268), G1.1>A (269), S29>K (300) (265-373),CH3 E12 (389), E13>Q (390), M14 (391), S20>K (397), M107>L (461), N114>S (467) (374-478), CHS (479-480)]]; dimer (234-260'':237-263'')-bisdisulfide, produced in Chinese Hamster Ovary (CHO)-S cell line, glycoform alfa (Source: WHO pINN list 123)

# STRUCTURAL FORMULA

## Heavy chain X (anti-ICOS)

QVQLVQSGAE	VKKPGASVKV	SCKASGYTFT	GYMHVWRQA	PGQGLEWMGW	50
INPHSGGTNY	AQKFQGRVTM	TRDTSISTAY	MELSRLRSDD	TAVYYCARTY	100
YDSSGGYYHD	AFDIWQGQTM	VTVSSASTKG	PSVFLAPLSS	KSTSGGTAAL	150
GCLVKDYFPE	PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSS	200
LGTQTYICNV	NHKPSDTKVD	KKVEPKSCDK	THTCPPCPAP	PVAGPSVFLF	250
PPKPKDTLMI	SRTPEVTCVV	VDVKHEDPEV	KFNWYVDGVE	VHNAKTKPRE	300
EEYNSTYRVV	SVLTVLHQDW	LNGKEYKCKV	SNKALPAPIE	KTISKAKGQP	350
REPQVYTLPP	SREEMTKNQV	SLTCDVSGFY	PSDIAVEWES	DGQPENNYKT	400
TPPVLDSDGS	FFLYSKLTVD	KSRWEQGDVF	SCSVLHEALH	SHYTQKLSL	450
SPGK					454

## Light chain X' (anti-ICOS)

DIQMTQSPSS	VSASVGDVRT	ITCRASQGIS	RLLAQQQKP	GKAPKLLIYV	50'
ASSLQSGVPS	RFSGSGSGTD	FLLTISSLQP	EDFATYYCQQ	ANSFPWTFGQ	100'
GTKVEIKRTV	AAPSFIFFP	SDEQLKSGTA	SVVCLLNIFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

## Chain IG scFv-h-CH2-CH3 (anti-PDCD1)

EIVLTQSPAT	LSASPGERV	LTCRASQSVG	NDVAWYQQKP	GQAPRLLINY	50''
ASHRYTGVPD	RFTGSGYGTE	FLLTISSVQS	EDFGVYYCQQ	DFSSPRTFGG	100''
GTKVEIKGKP	GSGKPGSGKP	GSGKPGSEVQ	LVESGGGLVK	PGGSLRLSCV	150''
ASGFTFSNYW	MNWVRQAPGK	GLEWVAEIRL	YSNNYATHYA	ESVKGRFTIS	200''
RDDSKSTLYL	QMNNLKTEDT	GVYYCTRYYG	NYGGYFDVWG	RGLVTVSSE	250''
PKSSDKTHTC	PPCPAPPVAG	PSVFLFPPKP	KDTLMISRTP	EVTCCVVVDVK	300''
HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	STYRVVSVLT	VLHQDWLNGK	350''
EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	VYTLPPSREQ	MTKNQVKLTC	400''
LVKGFYPSDI	AVEWESNGQP	ENNYKTTPPV	LDSDGSEFFLY	SKLTVDKSRW	450''
QQGNVVFSCSV	LHEALHSHYT	QKSLSLSPGK			480''

## Disulfide bridges

22-96	23'-88'	23''-88''	134'-194'	149''-225''	152-208	228-214'
234-260''	237-263''	268-328	294''-354''	374-432	400''-458''	

## Glycosylation sites (N)

304	330''
-----	-------

MOLECULAR FORMULA

C<sub>5622</sub>H<sub>8636</sub>N<sub>1502</sub>O<sub>1738</sub>S<sub>38</sub>

MOLECULAR WEIGHT

126.3

TRADEMARK

None as yet

SPONSOR

Xencor, Inc.

CODE DESIGNATIONS

XmAb23104

CAS REGISTRY NUMBER

2329669-80-7

UNII

9D2R4T39AY

WHO NUMBER

11466

gbk